By ordering Monoclonal Antibody Therapeutics 2009-2024 you will:

Find out the market prognosis for the global monoclonal antibody therapeutics market and for the relevant markets in oncology, autoimmune disorders and other therapeutic areas from 2009 to 2024

Receive comprehensive market forecasts and competitive analyses for leading monoclonal antibodies, including Rituximab, Avastin, Herceptin, Erbitux, Remicade, Humira, Xolair, Tysabri, Lucentis and Synagis, and for potential blockbusters of the future

Read expert views from key-opinion leaders in the monoclonal antibody field, with full interview transcripts provided

Examine strengths, weakness, opportunities and threats (SWOT) facing major stakeholders in the industry, including the prospects for biosimilar monoclonal antibodies

Discover market forecasts for the leading monoclonal antibody country markets and for the emerging markets of China and India

Analyse the monoclonal antibody therapeutics pipeline, especially for late-stage candidates, including the prospects for antibody fragments and antibody-drug conjugates.

reportlinker/p0151198/Reportlinker-Adds-Monoclonal-Antibody-Therapeutics-2009-2024.html